Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455325 · ClinicalTrials.gov registry record · Phase 2
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00455325: Completed Phase 2 study, sponsored by Washington University School of Medicine.
NCT00455325 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00455325, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the short-term effectiveness of chloroquine, a protein-activation medication, at improving metabolic syndrome.
Primary Outcome
Hepatic insulin sensitivity was measured by comparing glucose production at baseline of zero insulin infusion rate with glucose production at 56 pmol/m2/min. Hepatic insulin sensitivity was expressed as the percent suppression, such that greater percent suppression indicated greater hepatic insulin sensitivity. There are no reference values, since the patients served as their own controls.
Interventions
- DRUG Placebo Comparator: First Intervention (3 weeks)
- DRUG Active Comparator: Second Intervention (3 weeks)
- DRUG Active Comparator: Third Intervention (3 weeks)
- DRUG Active Comparator: Fourth Intervention (3 weeks)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2004-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT00455325 record still lists
NCT00455325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo Comparator: First Intervention (3 weeks) is the first listed.
NCT00455325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00455325 about?
NCT00455325 is a clinical study titled "Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)". Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the short-term effectiveness of chloroquine, a protein-activation medication, at improving metabolic syndrom...
What is the current status of trial NCT00455325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2004-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00455325?
The interventions under investigation include: Placebo Comparator: First Intervention (3 weeks) (DRUG), Active Comparator: Second Intervention (3 weeks) (DRUG), Active Comparator: Third Intervention (3 weeks) (DRUG), Active Comparator: Fourth Intervention (3 weeks) (DRUG).
Who is sponsoring clinical trial NCT00455325?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00455325's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia